STOCK TITAN

Tandem Diabetes Care: Sheridan stock awards vest

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Tandem Diabetes Care director and former president and CEO John F. Sheridan reported that 5,983 and 9,934 restricted stock units vested on November 15, 2026, with corresponding common shares acquired. The issuer withheld 3,045 and 5,055 shares, respectively, for tax withholding at the reported $20.07 per share; the footnote says no shares were sold.

Insider Sheridan John F
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Unit F2, F3, F4 5,983 $0.00 $0.00
Exercise Restricted Stock Unit F5, F3, F6 9,934 $0.00 $0.00
Exercise Common Stock 5,983 $0.00 $0.00
Tax Withholding Common Stock F1 3,045 $20.07 $61K
Exercise Common Stock 9,934 $0.00 $0.00
Tax Withholding Common Stock F1 5,055 $20.07 $101K
Holdings After Transaction: Restricted Stock Unit — 71,567 units (Direct); Common Stock — 168,077 shares (Direct)
Holdings Before and After: Restricted Stock Unit, 87,484 to 71,567 units (Direct); Common Stock, 160,260 to 168,077 shares (Direct)
Footnotes (6)
  1. F1. Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
  2. F2. Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
  3. F3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
  4. F4. One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
  5. F5. Awarded on May 30, 2025 pursuant to the 2023 Plan.
  6. F6. One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
Restricted stock units vested 5,983 shares November 15, 2026; corresponding common shares were acquired
Restricted stock units vested 9,934 shares November 15, 2026; corresponding common shares were acquired
Common shares acquired 5,983 shares Upon vesting of restricted stock units on November 15, 2026
Common shares acquired 9,934 shares Upon vesting of restricted stock units on November 15, 2026
Shares withheld for tax withholding 3,045 shares November 15, 2026; reported price was $20.07 per share
Shares withheld for tax withholding 5,055 shares November 15, 2026; reported price was $20.07 per share
Restricted Stock Unit financial
"vesting of restricted stock units (RSUs)"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
contingent right financial
"Each RSU represents a contingent right to receive either one share"
2023 Long-Term Incentive Plan financial
"pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan"
tax withholding requirements financial
"to satisfy tax withholding requirements upon the vesting of restricted stock units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TNDM shares did John F. Sheridan have withheld for taxes?

The issuer withheld 3,045 shares and 5,055 shares for tax withholding when restricted stock units vested on November 15, 2026. The reported price for each withholding transaction was $20.07 per share.

When were John F. Sheridan's TNDM restricted stock units granted and how do they vest?

The 5,983 RSUs were awarded May 23, 2024; one-third vested May 15, 2025, with the remainder vesting in eight equal quarterly installments thereafter. The 9,934 RSUs were awarded May 30, 2025; one-third vested May 15, 2026, with the remainder vesting in eight equal quarterly installments thereafter, subject to the 2023 Plan.

Did John F. Sheridan sell TNDM shares on November 15, 2026?

No shares were sold. The issuer withheld shares to satisfy tax withholding requirements upon vesting of the restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sheridan John F

(Last)(First)(Middle)
12400 HIGH BLUFF DRIVE

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)XOther (specify below)
FORMER PRESIDENT & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/15/2026M5,983A$0166,243D
Common Stock11/15/2026F(1)3,045D$20.07163,198D
Common Stock11/15/2026M9,934A$0173,132D
Common Stock11/15/2026F(1)5,055D$20.07168,077D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(2)(3)11/15/2026M5,983 (4) (4)Common Stock5,983$011,964D
Restricted Stock Unit(5)(3)11/15/2026M9,934 (6) (6)Common Stock9,934$059,603D
Explanation of Responses:
1. Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
2. Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
4. One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
5. Awarded on May 30, 2025 pursuant to the 2023 Plan.
6. One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
Remarks:
/s/ Jerilyn Laskie, Attorney-in-Fact for John F. Sheridan11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading